Cantor Fitzgerald Estimates AQST FY2025 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Aquestive Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($0.65) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price target on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same period last year, the firm posted ($0.03) earnings per share.

Several other equities analysts also recently weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Finally, Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Stock Down 2.2 %

NASDAQ AQST opened at $3.14 on Wednesday. Aquestive Therapeutics has a 52 week low of $2.24 and a 52 week high of $6.23. The company has a market capitalization of $286.31 million, a P/E ratio of -6.98 and a beta of 2.71. The stock’s 50-day moving average price is $3.86 and its 200-day moving average price is $4.19.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AQST. Financial Advocates Investment Management boosted its holdings in shares of Aquestive Therapeutics by 14.7% during the 3rd quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock valued at $194,000 after purchasing an additional 5,000 shares during the last quarter. nVerses Capital LLC bought a new position in Aquestive Therapeutics during the third quarter valued at approximately $28,000. SG Americas Securities LLC grew its holdings in Aquestive Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after buying an additional 7,347 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Aquestive Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock valued at $1,014,000 after buying an additional 9,268 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $27,000. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.